

**Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman - The Hashemite Kingdom of Jordan**

**Interim condensed Financial Statements  
and Independent Auditor's Report  
for the six months ended June 30, 2023**

Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman – The Hashemite Kingdom of Jordan

Index

|   | <u>Page</u> |
|---|-------------|
| Report on review of interim condensed financial information   | -           |
| Interim condensed statement of financial position as at June 30, 2023 (reviewed and unaudited)                      | 1           |
| Interim condensed statement of comprehensive income for the six months ended June 30, 2023 (reviewed and unaudited) | 2           |
| Interim condensed statement of changes in equity for the six months ended June 30, 2023 (reviewed and unaudited)    | 3           |
| Interim condensed statement of cash flows for the six months ended June 30, 2023 (reviewed and unaudited)           | 4           |
| Notes to the interim condensed financial information for the six months ended June 30, 2023                         | 5-7         |

105181287

## Report on review of interim condensed financial information

To Messrs. Shareholders  
Arab Center for Pharmaceutical & Chemical Industries Co  
Public Shareholding Company  
Amman – The Hashemite Kingdom of Jordan

### Introduction

We have reviewed the interim condensed statement of financial position of Arab Center for Pharmaceutical & Chemical Industries Co. (Public Shareholding Company) as at June 30, 2023, and the interim condensed statements of comprehensive income, changes in equity and cash flows for the six months then ended. Management is responsible for the preparation and fair representation of this interim financial information in accordance with International Accounting Standard IAS (34) "Interim financial reporting". Our responsibility is to express a conclusion about this interim financial information based on our review.

### Scope of Review

We conducted our review in accordance with International Standard on Review Engagement no. (2410) "Review of interim financial information performed by the independent auditor of the entity". A review of consolidated interim condensed financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed financial information is not prepared, in all material respects, in accordance with International Financial Reporting Standard no. (34) "Interim Financial Reporting".





Independent Auditor's Report for the six months ended June 30, 2023

**Going concern**

We would like to refer to note (5) of the Interim condensed financial statements where the accumulated losses for the company amounted to JD 7,407,588 as at June 30, 2023 representing 148% of the company's capital, also note that the company's current liabilities exceeded its current assets by an amount of JD 2,603,233, in addition to the existence of accrued liabilities that were not paid to date. These matters cast significant doubt on the company ability to continue as a going concern which requires it to comply with article no.(266) of the company's law, and its continuation depends on providing sufficient funds to meet its obligations and the success of its operations in the future. Based on the extraordinary meeting of the general assembly on March 29, 2023 the following decisions were taken to amortize the accumulated losses as follows:

- Agree to amortizing some of the accumulated losses amounted of JD 7,409,528 as on December 31, 2021 by decreasing the company's capital by an amount of JD 4,500,000 , to become the company's capital and the paid-in capital become JD 500,000 and the accumulated losses become JD 2,809,528 then use the whole statutory reserve balance of JD 1,138,105 as on December 31, 2021 to amortize part of the accumulated losses to its balance to become JD 1,671,423.
- Approval of increasing the capital of the company by an amount of JD 4,500,000 for the capital to become JD 5,000,000 instead of JD 500,000.

Upon completion of the above procedures the accumulated losses will be 35% of the company's capital, the extraordinary meeting of the general assembly decisions has not been executed until the date of the financial statements report.

**Emphasis of matter**

- We would like to state that there are restrains on the lands, buildings, vehicles and current accounts at banks, in addition to a restrain on the company's registration as shown in the company's registration certificate issued by the Ministry of Industry and Trade-Companies Control Department against outstanding foreseeable before the courts .
- We would like to refer to note (3) the project under construction which started on March 2013 is still not complete till date, knowing that the disputes with contractor at arbitration committee to resolve it.

Talal Abu-Ghazaleh & Co. International



Mohammad Al-Azraq  
(License # 1000)

Amman, July 27, 2023

Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman – The Hashemite Kingdom of Jordan

Interim condensed statement of financial position as at June 30, 2023 – (Reviewed and unaudited)

|  |       | June 30,2023             | December 31,2022        |
|--|-------|--------------------------|-------------------------|
|  | Notes | (Reviewed and unaudited) | (Audited)               |
|  |       | JD                       | JD                      |
| <b>ASSETS</b>  |       |                          |                         |
| <b>Non-current Assets</b>  |       |                          |                         |
| Property, plant and equipment  | 3     | 4,480,308                | 4,491,944               |
| Investment in an associate   | 4     | -                        | -                       |
| Investment in financial asset at fair value through other comprehensive income                           |       | 1                        | 1                       |
| Due from related parties   |       | 1,282,180                | 1,282,820               |
| <b>Total Non-Current Assets</b>  |       | <u>5,762,489</u>         | <u>5,774,765</u>        |
| <b>Current Assets</b>  |       |                          |                         |
| Inventory  |       | 138,913                  | 92,221                  |
| Other debit balances   |       | 60,774                   | 52,190                  |
| Trade receivables  |       | 13,505                   | 12,244                  |
| Cash and cash equivalents  |       | 19,816                   | 19,609                  |
| <b>Total Current Assets</b>  |       | <u>233,008</u>           | <u>176,264</u>          |
| <b>TOTAL ASSETS</b>  |       | <u><u>5,995,497</u></u>  | <u><u>5,951,029</u></u> |
| <b>EQUITY AND LIABILITIES</b>  |       |                          |                         |
| <b>Equity</b>  |       |                          |                         |
| Declared and paid capital  |       | 5,000,000                | 5,000,000               |
| Statutory reserve  |       | 1,138,105                | 1,138,105               |
| Change in fair value of investments in financial assets at fair value through other comprehensive income |       | (115,457)                | (115,457)               |
| Accumulated losses   | 5     | (7,407,588)              | (7,405,829)             |
| <b>Deficit in Equity</b>   |       | <u>(1,384,940)</u>       | <u>(1,383,181)</u>      |
| <b>Liabilities</b>   |       |                          |                         |
| <b>Non Current Liabilities</b>   |       |                          |                         |
| Shareholders' payable  |       | 4,544,196                | 4,543,896               |
| <b>Current Liabilities</b>   |       |                          |                         |
| Other credit balances  |       | 802,301                  | 787,774                 |
| Trade payables   |       | 437,448                  | 407,148                 |
| Due to related parties   |       | 1,596,492                | 1,595,392               |
| <b>Total Current Liabilities</b>   |       | <u>2,836,241</u>         | <u>2,790,314</u>        |
| <b>Total Liabilities</b>   |       | <u>7,380,437</u>         | <u>7,334,210</u>        |
| <b>TOTAL EQUITY AND LIABILITIES</b>  |       | <u><u>5,995,497</u></u>  | <u><u>5,951,029</u></u> |

The accompanying notes constitute an integral part of these financial statements

Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman - The Hashemite Kingdom of Jordan

**Interim condensed statement of comprehensive income for the six months ended June 30, 2023 -  
(Reviewed and unaudited)**

|                                   | For the six months ended on June 30 |            | For the three months ended on June 30 |          |
|-----------------------------------|-------------------------------------|------------|---------------------------------------|----------|
|                                   | 2023                                | 2022       | 2023                                  | 2022     |
|                                   | JD                                  | JD         | JD                                    | JD       |
| Sales                             | 83,889                              | 51,401     | 45,447                                | 9,685    |
| Cost of sales                     | (54,754)                            | (47,847)   | (31,123)                              | (21,260) |
| Gross profit (loss)               | 29,135                              | 3,554      | 14,324                                | (11,575) |
| Other revenues, net               | 2,900                               | 2,600      | 1,300                                 | 1,301    |
| Administrative expenses           | (33,794)                            | (65,270)   | (14,080)                              | (46,543) |
| Loss                              | (1,759)                             | (59,116)   | 1,544                                 | (56,817) |
| Weighted average number of shares | 5,000,000                           | 5,000,000  |                                       |          |
| Loss per share                    | JD (0/0004)                         | JD (0/012) |                                       |          |

The accompanying notes constitute an integral part of these financial statements



Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman – The Hashemite Kingdom of Jordan

Interim condensed statement of changes in equity for the six months ended June 30, 2023 – (Reviewed and unaudited)

|   | Capital   | Statutory reserve | Change in fair value of<br>investments in financial<br>assets at fair value<br>through other<br>comprehensive income | Accumulated<br>losses | Deficit     |
|---|-----------|-------------------|--|-----------------------|-------------|
|   | JD        | JD                | JD   | JD                    | JD          |
| <b>For the six months ended June 30 ,2023</b> |           |                   |  |                       |             |
| Balance as at January 1, 2023                 | 5,000,000 | 1,138,105         | (115,457)  | (7,405,829)           | (1,383,181) |
| Loss  | -         | -                 | -  | (1,759)               | (1,759)     |
| Balance as at June 30, 2023                   | 5,000,000 | 1,138,105         | (115,457)  | (7,407,588)           | (1,384,940) |
| <b>For the six months ended June 30 ,2022</b> |           |                   |  |                       |             |
| Balance as at January 1, 2022                 | 5,000,000 | 1,138,105         | (115,457)  | (7,309,528)           | (1,286,880) |
| Loss  | -         | -                 | -  | (59,116)              | (59,116)    |
| Balance as at June 30, 2022                   | 5,000,000 | 1,138,105         | (115,457)  | (7,368,644)           | (1,345,996) |

The accompanying notes constitute an integral part of these financial statements

Arab Center for Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman - The Hashemite Kingdom of Jordan

Interim condensed statement of cash flows for the six months ended June 30, 2023 -  
(Reviewed and unaudited)

|   | June 30,<br>2023     | June 30,<br>2022    |
|---|----------------------|---------------------|
|   | JD                   | JD                  |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>     |                      |                     |
| Loss  | (1,759)              | (59,116)            |
| Adjustments for :                               |                      |                     |
| Depreciation                                    | 11,636               | 12,803              |
| Change in operating assets and liabilities:     |                      |                     |
| Inventory                                       | (46,692)             | (9,615)             |
| Other debit balances                            | (8,584)              | (2,974)             |
| Trade receivables                               | (1,261)              | 2,651               |
| Other credit balances                           | 14,527               | 41,417              |
| Trade payables                                  | 30,300               | 15,294              |
| Net cash from operating activities              | <u>(1,833)</u>       | <u>460</u>          |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>     |                      |                     |
| Shareholders payable                            | 300                  | 300                 |
| Related parties receivables                     | 1,740                | 1,550               |
| Net cash from financing activities              | <u>2,040</u>         | <u>1,850</u>        |
| Net change in cash and cash equivalents         | 207                  | 2,310               |
| Cash and cash equivalents - beginning of period | 19,609               | 2,291               |
| Cash and cash equivalents - end of period       | <u><u>19,816</u></u> | <u><u>4,601</u></u> |

The accompanying notes constitute an integral part of these financial statements



Arab Center For Pharmaceutical  
& Chemical Industries Co  
Public Shareholding Company  
Amman - The Hashemite Kingdom of Jordan

Notes to the financial statements

---

**1. Legal status and activity**

- The Company was established on July 5, 1983 and registered as a public shareholding company with the Ministry of Industry and Trade under the number (185).
- The main Company's activities are as follows:
  - Human liquid medication manufacturing
  - Human pills medication manufacturing
  - Human Suppositories medication manufacturing
  - Veterinarian antibiotics manufacturing
  - Veterinarian antibacterial manufacturing
  - Veterinarian vitamins manufacturing
  - Gelatin capsules manufacturing
- The financial statements were approved by the Board of Directors in its meeting held on. July 26, 2023.

**2. Financial statements preparation framework and significant accounting policies**

- The interim condensed financial information for the company were prepared according to the International Accounting Standard (34) "Interim Financial Reporting".
- Accounting policies used in preparing the interim condensed financial statement are consistent with those policies used in preparing the financial statements for the year ended December 31, 2022.

Notes to the financial statements for the six months ended June 30, 2023

3. Property, plant and equipment

| June 30, 2023               | Lands (*) | Buildings (*) | Furniture and decorations | Devices and machines | Software and computers | Electrical devices and condition units | Tools and equipment | Vehicles and machinery (*) | Projects under construction (**) | Total     |
|-----------------------------|-----------|---------------|---------------------------|----------------------|------------------------|--|---------------------|----------------------------|----------------------------------|-----------|
|                             | JD        | JD            | JD                        | JD                   | JD                     |  | JD                  | JD                         | JD                               | JD        |
| Cost                        |           |               |                           |                      |                        |  |                     |                            |                                  |           |
| Beginning of period balance | 322,476   | 1,216,723     | 208,255                   | 3,358,832            | 200,705                | 114,481                                | 27,007              | 36,582                     | 3,660,240                        | 9,145,301 |
| End of period balance       | 322,476   | 1,216,723     | 208,255                   | 3,358,832            | 200,705                | 114,481                                | 27,007              | 36,582                     | 3,660,240                        | 9,145,301 |
| Accumulated depreciation    |           |               |                           |                      |                        |  |                     |                            |                                  |           |
| Beginning of period balance | -         | 708,958       | 207,704                   | 3,358,106            | 200,598                | 114,410                                | 27,002              | 36,579                     | -                                | 4,653,357 |
| Depreciation                | -         | 11,557        | 62                        | 17                   | -                      | -                                      | -                   | -                          | -                                | 11,636    |
| End of period balance       | -         | 720,515       | 207,766                   | 3,358,123            | 200,598                | 114,410                                | 27,002              | 36,579                     | -                                | 4,664,993 |
| Net                         | 322,476   | 496,208       | 489                       | 709                  | 107                    | 71                                     | 5                   | 3                          | 3,660,240                        | 4,480,308 |
| December 31, 2022           |           |               |                           |                      |                        |  |                     |                            |                                  |           |
| Cost                        |           |               |                           |                      |                        |  |                     |                            |                                  |           |
| Beginning of year balance   | 322,476   | 1,216,723     | 208,255                   | 3,358,832            | 200,705                | 114,481                                | 27,007              | 36,582                     | 3,660,240                        | 9,145,301 |
| End of year balance         | 322,476   | 1,216,723     | 208,255                   | 3,358,832            | 200,705                | 114,481                                | 27,007              | 36,582                     | 3,660,240                        | 9,145,301 |
| Accumulated depreciation    |           |               |                           |                      |                        |  |                     |                            |                                  |           |
| Beginning of year balance   | -         | 685,493       | 207,669                   | 3,356,003            | 200,594                | 114,410                                | 27,002              | 36,579                     | -                                | 4,627,750 |
| Depreciation                | -         | 23,465        | 35                        | 2,103                | 4                      | -                                      | -                   | -                          | -                                | 25,607    |
| End of year balance         | -         | 708,958       | 207,704                   | 3,358,106            | 200,598                | 114,410                                | 27,002              | 36,579                     | -                                | 4,653,357 |
| Net                         | 322,476   | 507,765       | 551                       | 726                  | 107                    | 71                                     | 5                   | 3                          | 3,660,240                        | 4,491,944 |

(\*) Lands, buildings, vehicles and machinery are seized against legal cases held at related courts, and is still outstanding as of the date of the financial statements.

(\*\*) Project under construction represent the company's building and facilities development and improvement, in addition to buying machinery and equipment in order to increase the production capacity to replace certain production lines, and to change the factory infrastructure and renovate buildings to bring the factory into line with conditions of the drug production process that's where started on March 2013.

Notes to the financial statements for the six months ended June 30, 2023

4. Investment in an associate

| Company   | Country of<br>incorporation | Legal entity | Ownership | Total assets | Total liabilities | Loss      | Accumulated losses |
|---|-----------------------------|--------------|-----------|--------------|-------------------|-----------|--------------------|
|   |                             |              |           | JD           | JD                | JD        | JD                 |
| Middle East Pharmaceutical and chemical<br>Industries and Medical Appliances<br>Company | Jordan                      | P.L.C        | 12,85     | 8,428,646    | 23,148,560        | (578,679) | (21,409,010)       |

(\*) Movement of investment through the period was as the follows:

|                               | June 30, 2023 | December 31, 2022 |
|-------------------------------|---------------|-------------------|
|                               | JD            | JD                |
| Cost                          | 51,573        | 51,573            |
| Share of results of associate | (51,573)      | (51,573)          |
| Net                           | -             | -                 |

5. Accumulated losses

The company's accumulated losses amounted to JD 7,407,588 which represents 148% of its capital as at June 30, 2023, follows a summary of the company's plan:

- End the conflict with the contractor as soon as possible and then complete the final stages of the expansion project and the start of the actual production process on the new lines, and this leads to re-entry into the traditional markets and opening new markets.
- The general assembly held an extraordinary meeting on March 29, 2022 and the following decisions were made:
  - Agree to amortizing some of the accumulated losses amounted of JD 7,309,528 as on December 31, 2021 by decreasing the company's capital by quenching the amount of JD 4,500,000 so the capital and the paid-in capital become JD 500,000 and the accumulated losses become JD 2,809,528 then use the whole statutory reserve which is amounted to 1,138,105 as on December 31, 2021 to amortize part of the accumulated losses to become JD 1,671,423.
  - Increase the capital of the company by an amount of JD 4,500,000 to become JD 5,000,000 instead of JD 500,000 by capitalizing part of the company's shareholders payables as follows:

| Creditor                     | Capitalized amount<br>(JD) |
|------------------------------|----------------------------|
| Hamzeh Tantash               | 2,612,914                  |
| Tantash Investment Group Co. | 1,529,542                  |
| Mazen Tantash                | 357,544                    |
| <b>Total</b>                 | <b>4,500,000</b>           |

- The extraordinary meeting of the general assembly decisions has not been executed until the date of the financial statements report.

6. The potential effects of economic fluctuations

As a result of the current global conflict, where the entity has taken into account any possible impact of current economic fluctuations in the inputs of future macroeconomic factors when determining the severity and probability of economic scenarios to determine expected credit losses.